JPWO2020243379A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020243379A5
JPWO2020243379A5 JP2021570866A JP2021570866A JPWO2020243379A5 JP WO2020243379 A5 JPWO2020243379 A5 JP WO2020243379A5 JP 2021570866 A JP2021570866 A JP 2021570866A JP 2021570866 A JP2021570866 A JP 2021570866A JP WO2020243379 A5 JPWO2020243379 A5 JP WO2020243379A5
Authority
JP
Japan
Prior art keywords
carboxamide
dioxopiperidin
oxo
isoindoline
trifluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021570866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534979A (ja
JP7496838B2 (ja
JP2022534979A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035043 external-priority patent/WO2020243379A1/en
Publication of JP2022534979A publication Critical patent/JP2022534979A/ja
Publication of JPWO2020243379A5 publication Critical patent/JPWO2020243379A5/ja
Publication of JP2022534979A5 publication Critical patent/JP2022534979A5/ja
Priority to JP2024086242A priority Critical patent/JP2024123001A/ja
Application granted granted Critical
Publication of JP7496838B2 publication Critical patent/JP7496838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570866A 2019-05-31 2020-05-29 置換1-オキソ-イソインドリン-5-カルボキサミド化合物、その組成物、およびそれによる治療方法 Active JP7496838B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086242A JP2024123001A (ja) 2019-05-31 2024-05-28 置換1-オキソ-イソインドリン-5-カルボキサミド化合物、その組成物、およびそれによる治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855619P 2019-05-31 2019-05-31
US62/855,619 2019-05-31
PCT/US2020/035043 WO2020243379A1 (en) 2019-05-31 2020-05-29 Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086242A Division JP2024123001A (ja) 2019-05-31 2024-05-28 置換1-オキソ-イソインドリン-5-カルボキサミド化合物、その組成物、およびそれによる治療方法

Publications (4)

Publication Number Publication Date
JP2022534979A JP2022534979A (ja) 2022-08-04
JPWO2020243379A5 true JPWO2020243379A5 (https=) 2023-05-30
JP2022534979A5 JP2022534979A5 (https=) 2023-05-30
JP7496838B2 JP7496838B2 (ja) 2024-06-07

Family

ID=73551319

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570866A Active JP7496838B2 (ja) 2019-05-31 2020-05-29 置換1-オキソ-イソインドリン-5-カルボキサミド化合物、その組成物、およびそれによる治療方法
JP2024086242A Pending JP2024123001A (ja) 2019-05-31 2024-05-28 置換1-オキソ-イソインドリン-5-カルボキサミド化合物、その組成物、およびそれによる治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086242A Pending JP2024123001A (ja) 2019-05-31 2024-05-28 置換1-オキソ-イソインドリン-5-カルボキサミド化合物、その組成物、およびそれによる治療方法

Country Status (19)

Country Link
US (2) US11306101B2 (https=)
EP (1) EP3976595A4 (https=)
JP (2) JP7496838B2 (https=)
KR (2) KR20250078628A (https=)
CN (4) CN119930578A (https=)
AR (1) AR119057A1 (https=)
AU (1) AU2020282748A1 (https=)
BR (1) BR112021022758A2 (https=)
CA (1) CA3136753A1 (https=)
CL (1) CL2021003134A1 (https=)
CO (1) CO2021015624A2 (https=)
IL (1) IL288278B2 (https=)
MX (1) MX2021014350A (https=)
MY (1) MY208545A (https=)
PE (1) PE20220569A1 (https=)
SG (1) SG11202112872YA (https=)
TW (2) TW202523657A (https=)
WO (1) WO2020243379A1 (https=)
ZA (1) ZA202109003B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243379A1 (en) 2019-05-31 2020-12-03 Celgene Corporation Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
IL302038A (en) * 2020-10-14 2023-06-01 C4 Therapeutics Inc Tricyclic ligands for degradation of ikzf2 or ikzf4
CN112679421A (zh) * 2021-01-04 2021-04-20 都创(上海)医药科技股份有限公司 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス, インコーポレイテッド イソインドリノン化合物
CN118019534A (zh) * 2021-05-06 2024-05-10 细胞基因公司 使用n-((r)-1-(3-氯吡啶-2-基)-2,2,2-三氟乙基)-2-((s)-2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-甲酰胺的治疗方法
US20240294500A1 (en) * 2021-06-08 2024-09-05 Hangzhou Glubio Pharmaceutical Co., Ltd. Isoindolinone compounds, and uses thereof
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
WO2023244815A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
WO2023244818A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
US20260055077A1 (en) * 2022-08-01 2026-02-26 Suzhou Kintor Pharmaceuticals, Inc. Protein degradation agent
WO2024120441A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2024120438A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 一种固体分散体、其制备方法和应用
PL249026B1 (pl) * 2022-12-09 2026-02-23 Univ Mikolaja Kopernika W Toruniu Pochodna azetydyno-2,4-dionu, sposób jej otrzymywania i zastosowanie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
KR20080042158A (ko) * 2005-08-31 2008-05-14 셀진 코포레이션 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
MX2009001989A (es) 2006-08-30 2009-03-09 Celgene Corp Compuestos de isoindolina 5-substituidos.
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
ZA200901078B (en) * 2006-08-30 2010-06-30 Celgene Corp 5-substituted isoindoline compounds
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2020243379A1 (en) 2019-05-31 2020-12-03 Celgene Corporation Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Similar Documents

Publication Publication Date Title
JPWO2020243379A5 (https=)
JP2017525757A5 (https=)
CN114761086B (zh) 作为parp7抑制剂的哒嗪酮
JP2021524484A5 (https=)
US10287266B2 (en) Compounds and compositions for inhibiting the activity of SHP2
TWI491603B (zh) 甲吡啶醯胺(picolinamide)與嘧啶-4-甲醯胺化合物、其製造方法及含其之醫藥組合物
JP2018530571A5 (https=)
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
HRP20120457T1 (hr) 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba
JP2013515688A (ja) Jak阻害剤としてのイミダゾピリジン誘導体
JPWO2020012334A5 (https=)
JP2013519733A5 (https=)
JP2017505794A5 (https=)
JP2013537174A5 (https=)
JP2012525395A5 (https=)
JP2008519765A5 (https=)
CN104080774A (zh) 吡嗪甲酰胺化合物
JP2017519023A5 (https=)
JP2010535799A5 (https=)
JP2018522886A (ja) mIDH1阻害剤としての2−アリール−および2−アリールアルキル−ベンズイミダゾール
JP2021511324A5 (https=)
WO2021003417A1 (en) Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
AU2023330130A1 (en) Compounds and methods for modulating her2
JP2013522372A5 (https=)
US20250345339A1 (en) Doses and regimens of her2 inhibitors